COMP <GO>
ALKS vs LLY // EV/EBITDA & P/E VALUATION
Alkermes plc (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ALKS 4
— LLY 11
▲ EV/EBITDA & P/E VALUATION LEADER: ALKS
LAST: $45.34 (-0.07%) • MKT CAP: $7.61B
valuation
25.1x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALKS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALKS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.70% | 83.64% | +3.06 | ALKS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.00% | 32.36% | -18.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 25.1x | 36.4x | -11.32 | ALKS | /valuation <GO> |
| Free Cash Flow Yield | 6.31% | 2.30% | +4.01 | ALKS | /fcf-yield <GO> |
| Operating Margin | 17.20% | 40.21% | -23.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | 16.40% | 31.90% | -15.50 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -5.20% | 45.51% | -50.71 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.03 | 9.29 | -1.26 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.77% | +0.33 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.1 | 77.9 | -16.75 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.51 | +0.54 | ALKS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.3x | 26.3x | +3.05 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.61B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALKS REV | LLY REV | ALKS GROSS % | LLY GROSS % | ALKS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.48B | $65.18B | 86.7% | 83.0% | $480.3M | $16.81B |
| FY 2024 | $1.56B | $45.04B | 84.2% | 81.3% | $405.6M | $8.82B |
| FY 2023 | $1.66B | $34.12B | 44.0% | 79.3% | $326.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALKS // BETA 1.05
LLY // BETA 0.51